{
  "DOI": "10.1007/s10689-022-00313-0",
  "ISSN": [
    "1389-9600",
    "1573-7292"
  ],
  "URL": "http://dx.doi.org/10.1007/s10689-022-00313-0",
  "alternative-id": [
    "313"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "20 June 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "13 August 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "27 August 2022"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "Dr Nazneen Rahman is a Non-executive Director of AstraZeneca."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0001-9201-9216",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "McVeigh",
      "given": "Terri Patricia",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Sweeney",
      "given": "Karl J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Brennan",
      "given": "Donal J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "McVeigh",
      "given": "Una M.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Ward",
      "given": "Simon",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Strydom",
      "given": "Ann",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Seal",
      "given": "Sheila",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Astbury",
      "given": "Katherine",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Donnellan",
      "given": "Paul",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Higgins",
      "given": "Joanne",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Keane",
      "given": "Maccon",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Kerin",
      "given": "Michael J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Malone",
      "given": "Carmel",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "McGough",
      "given": "Pauline",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "McLaughlin",
      "given": "Ray",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "O’Leary",
      "given": "Michael",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Rushe",
      "given": "Margaret",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Barry",
      "given": "Michael Kevin",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "MacGregor",
      "given": "Geraldine",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Sugrue",
      "given": "Michael",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Yousif",
      "given": "Ala",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Al-Azawi",
      "given": "Dhafir",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Berkeley",
      "given": "Eileen",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Boyle",
      "given": "Terence J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Connolly",
      "given": "Elizabeth M.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Nolan",
      "given": "Carmel",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Richardson",
      "given": "Elaine",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Giffney",
      "given": "Claire",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Doyle",
      "given": "Samantha B.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Broderick",
      "given": "Sheila",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Boyd",
      "given": "William",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "McVey",
      "given": "Ruaidhri",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Walsh",
      "given": "Thomas",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Farrell",
      "given": "Michael",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Gallagher",
      "given": "David J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Rahman",
      "given": "Nazneen",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "George",
      "given": "Angela J.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Familial Cancer"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2022,
        8,
        27
      ]
    ],
    "date-time": "2022-08-27T06:05:01Z",
    "timestamp": 1661580301000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        3,
        27
      ]
    ],
    "date-time": "2023-03-27T00:17:53Z",
    "timestamp": 1679876273000
  },
  "funder": [
    {
      "DOI": "10.13039/100014461",
      "award": [
        "098518"
      ],
      "doi-asserted-by": "publisher",
      "name": "NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research"
    },
    {
      "DOI": "10.13039/100010414",
      "award": [
        "HRB/HSE NSAFP 2014/1",
        "HRB KEDS-2017-043"
      ],
      "doi-asserted-by": "publisher",
      "name": "Health Research Board"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2023,
        6,
        13
      ]
    ],
    "date-time": "2023-06-13T16:19:15Z",
    "timestamp": 1686673155201
  },
  "is-referenced-by-count": 1,
  "issn-type": [
    {
      "type": "print",
      "value": "1389-9600"
    },
    {
      "type": "electronic",
      "value": "1573-7292"
    }
  ],
  "issue": "2",
  "issued": {
    "date-parts": [
      [
        2022,
        8,
        27
      ]
    ]
  },
  "journal-issue": {
    "issue": "2",
    "published-print": {
      "date-parts": [
        [
          2023,
          4
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            8,
            27
          ]
        ],
        "date-time": "2022-08-27T00:00:00Z",
        "timestamp": 1661558400000
      }
    },
    {
      "URL": "https://www.springernature.com/gp/researchers/text-and-data-mining",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            8,
            27
          ]
        ],
        "date-time": "2022-08-27T00:00:00Z",
        "timestamp": 1661558400000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-022-00313-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s10689-022-00313-0/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-022-00313-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "135-149",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2022,
        8,
        27
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2022,
        8,
        27
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2023,
        4
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1016/j.ygyno.2021.10.072",
      "author": "VM Witjes",
      "doi-asserted-by": "publisher",
      "first-page": "221",
      "issue": "1",
      "journal-title": "Gynecologic Oncol",
      "key": "313_CR1",
      "unstructured": "Witjes VM, van Bommel MHD, Ligtenberg MJL, Vos JR, Mourits MJE, Ausems MGEM et al (2022) Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma a meta-analysis. Gynecologic Oncol 164(1):221–230",
      "volume": "164",
      "year": "2022"
    },
    {
      "DOI": "10.1016/j.ygyno.2021.05.011",
      "author": "J Lin",
      "doi-asserted-by": "publisher",
      "first-page": "506",
      "issue": "2",
      "journal-title": "Gynecol Oncol",
      "key": "313_CR2",
      "unstructured": "Lin J, Sharaf RN, Saganty R, Ahsan D, Feit J, Khoury A et al (2021) Achieving universal genetic assessment for women with ovarian cancer: are we there yet? A systematic review and meta-analysis. Gynecol Oncol 162(2):506–516",
      "volume": "162",
      "year": "2021"
    },
    {
      "DOI": "10.1002/cncr.30498",
      "author": "SS Buys",
      "doi-asserted-by": "publisher",
      "first-page": "1721",
      "issue": "10",
      "journal-title": "Cancer",
      "key": "313_CR3",
      "unstructured": "Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL et al (2017) A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123(10):1721–1730",
      "volume": "123",
      "year": "2017"
    },
    {
      "DOI": "10.1200/JCO.18.01631",
      "author": "PD Beitsch",
      "doi-asserted-by": "publisher",
      "first-page": "453",
      "issue": "6",
      "journal-title": "J Clin Oncol",
      "key": "313_CR4",
      "unstructured": "Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G et al (2019) Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37(6):453–460",
      "volume": "37",
      "year": "2019"
    },
    {
      "DOI": "10.1016/S1470-2045(17)30891-4",
      "author": "ER Copson",
      "doi-asserted-by": "publisher",
      "first-page": "169",
      "issue": "2",
      "journal-title": "Lancet Oncol",
      "key": "313_CR5",
      "unstructured": "Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG et al (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 19(2):169–180",
      "volume": "19",
      "year": "2018"
    },
    {
      "DOI": "10.1245/s10434-013-3205-1",
      "author": "R Greenup",
      "doi-asserted-by": "publisher",
      "first-page": "3254",
      "issue": "10",
      "journal-title": "Ann Surg Oncol",
      "key": "313_CR6",
      "unstructured": "Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T et al (2013) Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 20(10):3254–3258",
      "volume": "20",
      "year": "2013"
    },
    {
      "DOI": "10.1136/jmedgenet-2011-100006",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "520",
      "issue": "8",
      "journal-title": "J Med Genet",
      "key": "313_CR7",
      "unstructured": "Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM (2011) Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 48(8):520–522",
      "volume": "48",
      "year": "2011"
    },
    {
      "DOI": "10.1038/s41436-019-0712-x",
      "author": "T Pal",
      "doi-asserted-by": "publisher",
      "first-page": "681",
      "issue": "4",
      "journal-title": "Genet Med",
      "key": "313_CR8",
      "unstructured": "Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M et al (2020) Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American college of medical genetics and genomics (ACMG). Genet Med 22(4):681–685",
      "volume": "22",
      "year": "2020"
    },
    {
      "DOI": "10.1186/s13053-017-0071-z",
      "author": "S Yadav",
      "doi-asserted-by": "publisher",
      "first-page": "11",
      "journal-title": "Hered Cancer Clin Pract",
      "key": "313_CR9",
      "unstructured": "Yadav S, Reeves A, Campian S, Sufka A, Zakalik D (2017) Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis. Hered Cancer Clin Pract 15:11–11",
      "volume": "15",
      "year": "2017"
    },
    {
      "DOI": "10.1200/JCO.2016.34.15_suppl.1586",
      "doi-asserted-by": "crossref",
      "key": "313_CR10",
      "unstructured": "Metcalfe KA, Narod S, Eisen A, Lerner-Ellis J (2016) Treatment decision making and psychosocial outcomes associated with rapid genetic testing for BRCA1 and BRCA2 in women newly diagnosed with breast cancer. J Clin Oncol 34 (15_suppl) 1586-1586"
    },
    {
      "DOI": "10.1186/s13053-018-0092-2",
      "author": "NH Sæther",
      "doi-asserted-by": "publisher",
      "first-page": "9",
      "journal-title": "Hered Cancer Clin Pract",
      "key": "313_CR11",
      "unstructured": "Sæther NH, Skuja E, Irmejs A, Maksimenko J, Miklasevics E, Purkalne G et al (2018) Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review. Hered Cancer Clin Pract 16:9–9",
      "volume": "16",
      "year": "2018"
    },
    {
      "DOI": "10.14694/EdBook_AM.2015.35.114",
      "author": "DS Tan",
      "doi-asserted-by": "publisher",
      "first-page": "114",
      "journal-title": "Am Soc Clin Oncol Educ Book",
      "key": "313_CR12",
      "unstructured": "Tan DS, Kaye SB (2015) Chemotherapy for patients with BRCA1 and BRCA2-mutated ovarian cancer: same or different? Am Soc Clin Oncol Educ Book 35:114–21",
      "volume": "35",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.annonc.2020.08.2102",
      "author": "RE Miller",
      "doi-asserted-by": "publisher",
      "first-page": "1606",
      "issue": "12",
      "journal-title": "Ann Oncol",
      "key": "313_CR13",
      "unstructured": "Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D et al (2020) ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol 31(12):1606–1622",
      "volume": "31",
      "year": "2020"
    },
    {
      "DOI": "10.1016/S1470-2045(17)30469-2",
      "author": "E Pujade-Lauraine",
      "doi-asserted-by": "publisher",
      "first-page": "1274",
      "issue": "9",
      "journal-title": "Lancet Oncol",
      "key": "313_CR14",
      "unstructured": "Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18(9):1274–1284",
      "volume": "18",
      "year": "2017"
    },
    {
      "DOI": "10.1056/NEJMoa1810858",
      "author": "K Moore",
      "doi-asserted-by": "publisher",
      "first-page": "2495",
      "issue": "26",
      "journal-title": "N Engl J Med",
      "key": "313_CR15",
      "unstructured": "Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495–2505",
      "volume": "379",
      "year": "2018"
    },
    {
      "DOI": "10.1200/JCO.2020.38.15_suppl.6002",
      "doi-asserted-by": "crossref",
      "key": "313_CR16",
      "unstructured": "Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM et al. (2020) Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol 38(15_suppl) 6002–6002"
    },
    {
      "DOI": "10.1016/S0140-6736(17)32440-6",
      "author": "RL Coleman",
      "doi-asserted-by": "publisher",
      "first-page": "1949",
      "issue": "10106",
      "journal-title": "Lancet",
      "key": "313_CR17",
      "unstructured": "Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10106):1949–1961",
      "volume": "390",
      "year": "2017"
    },
    {
      "DOI": "10.1056/NEJMoa1611310",
      "author": "MR Mirza",
      "doi-asserted-by": "publisher",
      "first-page": "2154",
      "issue": "22",
      "journal-title": "N Engl J Med",
      "key": "313_CR18",
      "unstructured": "Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154–2164",
      "volume": "375",
      "year": "2016"
    },
    {
      "DOI": "10.1056/NEJMoa1910962",
      "author": "A González-Martín",
      "doi-asserted-by": "publisher",
      "first-page": "2391",
      "issue": "25",
      "journal-title": "N Engl J Med",
      "key": "313_CR19",
      "unstructured": "González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381(25):2391–2402",
      "volume": "381",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1911361",
      "author": "I Ray-Coquard",
      "doi-asserted-by": "publisher",
      "first-page": "2416",
      "issue": "25",
      "journal-title": "N Engl J Med",
      "key": "313_CR20",
      "unstructured": "Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416–2428",
      "volume": "381",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1909707",
      "author": "RL Coleman",
      "doi-asserted-by": "publisher",
      "first-page": "2403",
      "issue": "25",
      "journal-title": "N Engl J Med",
      "key": "313_CR21",
      "unstructured": "Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M et al (2019) Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 381(25):2403–2415",
      "volume": "381",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1706450",
      "author": "M Robson",
      "doi-asserted-by": "publisher",
      "first-page": "523",
      "issue": "6",
      "journal-title": "N Engl J Med",
      "key": "313_CR22",
      "unstructured": "Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA Mutation. N Engl J Med 377(6):523–533",
      "volume": "377",
      "year": "2017"
    },
    {
      "DOI": "10.1056/NEJMoa1802905",
      "author": "JK Litton",
      "doi-asserted-by": "publisher",
      "first-page": "753",
      "issue": "8",
      "journal-title": "N Engl J Med",
      "key": "313_CR23",
      "unstructured": "Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763",
      "volume": "379",
      "year": "2018"
    },
    {
      "DOI": "10.1056/NEJMoa2105215",
      "author": "ANJ Tutt",
      "doi-asserted-by": "publisher",
      "first-page": "2394",
      "issue": "25",
      "journal-title": "N Engl J Med",
      "key": "313_CR24",
      "unstructured": "Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394–2405",
      "volume": "384",
      "year": "2021"
    },
    {
      "DOI": "10.1016/S1470-2045(19)30684-9",
      "author": "J Mateo",
      "doi-asserted-by": "publisher",
      "first-page": "162",
      "issue": "1",
      "journal-title": "Lancet Oncol",
      "key": "313_CR25",
      "unstructured": "Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R et al (2020) Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 21(1):162–174",
      "volume": "21",
      "year": "2020"
    },
    {
      "DOI": "10.1093/annonc/mdz446.007",
      "author": "SK Sandhu",
      "doi-asserted-by": "publisher",
      "first-page": "ix188",
      "journal-title": "Ann Oncol",
      "key": "313_CR26",
      "unstructured": "Sandhu SK, Hussain M, Mateo J, Fizazi K, Saad F, Shore N et al (2019) PROfound: phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Ann Oncol 30:ix188–ix189",
      "volume": "30",
      "year": "2019"
    },
    {
      "DOI": "10.1056/NEJMoa1903387",
      "author": "T Golan",
      "doi-asserted-by": "publisher",
      "first-page": "317",
      "issue": "4",
      "journal-title": "N Engl J Med",
      "key": "313_CR27",
      "unstructured": "Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381(4):317–327",
      "volume": "381",
      "year": "2019"
    },
    {
      "key": "313_CR28",
      "unstructured": "AstraZeneca KA (2022) Lynparza approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. AstraZeneca. Press release available from:  https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.html. Accessed 1 Jun 2022"
    },
    {
      "key": "313_CR29",
      "unstructured": "Merck, LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer (2022) Press release available from: https://www.merck.com/news/lynparza-olaparib-receives-positive-opinion-from-eu-chmp-as-adjuvant-treatment-for-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer/. Accessed 1 Jul 2022"
    },
    {
      "key": "313_CR30",
      "unstructured": "Gotlieb WH. (2017) The society of gynaecologic oncology of canada (GOC) position statement: no woman left behind: toward a pan-canadian strategy for universal BRCA testing in ovarian cancer"
    },
    {
      "key": "313_CR31",
      "unstructured": "National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer (2019)"
    },
    {
      "key": "313_CR32",
      "unstructured": "Ledermann JA, Sessa C, Colombo N. (2016) eUpdate—ovarian cancer treatment recommendations (ESMO guidelines committee)"
    },
    {
      "key": "313_CR33",
      "unstructured": "ACOG Practice Bulletine Clinical Management Guidelines for Obstetrician-Gynecologists. (2017). 130(3)"
    },
    {
      "DOI": "10.1016/j.ejca.2016.10.006",
      "author": "I Vergote",
      "doi-asserted-by": "publisher",
      "first-page": "127",
      "journal-title": "Eur J Cancer",
      "key": "313_CR34",
      "unstructured": "Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F et al (2016) Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer 69:127–134",
      "volume": "69",
      "year": "2016"
    },
    {
      "DOI": "10.1136/bmj.i6357",
      "author": "S Desai",
      "doi-asserted-by": "publisher",
      "journal-title": "BMJ",
      "key": "313_CR35",
      "unstructured": "Desai S, Jena AB (2016) Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie’s New York times editorial. BMJ 355:i6357",
      "volume": "355",
      "year": "2016"
    },
    {
      "DOI": "10.1038/ejhg.2012.271",
      "author": "L Henneman",
      "doi-asserted-by": "publisher",
      "first-page": "793",
      "issue": "8",
      "journal-title": "Eur J Hum Genet",
      "key": "313_CR36",
      "unstructured": "Henneman L, Vermeulen E, van El CG, Claassen L, Timmermans DR, Cornel MC (2013) Public attitudes towards genetic testing revisited: comparing opinions between 2002 and 2010. Eur J Hum Genet 21(8):793–799",
      "volume": "21",
      "year": "2013"
    },
    {
      "DOI": "10.1007/s11845-015-1373-7",
      "author": "TP McVeigh",
      "doi-asserted-by": "publisher",
      "first-page": "825",
      "issue": "4",
      "journal-title": "Ir J Med Sci",
      "key": "313_CR37",
      "unstructured": "McVeigh TP, Sweeney KJ, Kerin MJ, Gallagher DJ (2016) A qualitative analysis of the attitudes of Irish patients towards participation in genetic-based research. Ir J Med Sci 185(4):825–831",
      "volume": "185",
      "year": "2016"
    },
    {
      "DOI": "10.1007/s10897-017-0158-8",
      "author": "JM Hoskovec",
      "doi-asserted-by": "publisher",
      "first-page": "16",
      "issue": "1",
      "journal-title": "J Genet Couns",
      "key": "313_CR38",
      "unstructured": "Hoskovec JM, Bennett RL, Carey ME, DaVanzo JE, Dougherty M, Hahn SE et al (2018) Projecting the supply and demand for certified genetic counselors: a workforce study. J Genet Couns 27(1):16–20",
      "volume": "27",
      "year": "2018"
    },
    {
      "DOI": "10.1038/s41436-021-01162-5",
      "author": "BD Jenkins",
      "doi-asserted-by": "publisher",
      "first-page": "1458",
      "issue": "8",
      "journal-title": "Genet Med",
      "key": "313_CR39",
      "unstructured": "Jenkins BD, Fischer CG, Polito CA, Maiese DR, Keehn AS, Lyon M et al (2021) The 2019 US medical genetics workforce: a focus on clinical genetics. Genet Med 23(8):1458–1464",
      "volume": "23",
      "year": "2021"
    },
    {
      "DOI": "10.1038/s41436-018-0417-6",
      "author": "DR Maiese",
      "doi-asserted-by": "publisher",
      "first-page": "1874",
      "issue": "8",
      "journal-title": "Genet Med",
      "key": "313_CR40",
      "unstructured": "Maiese DR, Keehn A, Lyon M, Flannery D, Watson M, Working Groups of the National Coordinating Center for Seven Regional Genetics Service, C (2019) Current conditions in medical genetics practice. Genet Med 21(8):1874–1877",
      "volume": "21",
      "year": "2019"
    },
    {
      "DOI": "10.1038/s41436-019-0628-5",
      "author": "M Penon-Portmann",
      "doi-asserted-by": "publisher",
      "first-page": "227",
      "issue": "1",
      "journal-title": "Genet Med",
      "key": "313_CR41",
      "unstructured": "Penon-Portmann M, Chang J, Cheng M, Shieh JT (2020) Genetics workforce: distribution of genetics services and challenges to health care in California. Genet Med 22(1):227–231",
      "volume": "22",
      "year": "2020"
    },
    {
      "DOI": "10.1038/s41436-020-0825-2",
      "author": "N Dragojlovic",
      "doi-asserted-by": "publisher",
      "first-page": "1437",
      "issue": "9",
      "journal-title": "Genet Med",
      "key": "313_CR42",
      "unstructured": "Dragojlovic N, Borle K, Kopac N, Ellis U, Birch P, Adam S et al (2020) The composition and capacity of the clinical genetics workforce in high-income countries: a scoping review. Genet Med 22(9):1437–1449",
      "volume": "22",
      "year": "2020"
    },
    {
      "DOI": "10.12688/hrbopenres.13187.1",
      "author": "C Seoighe",
      "doi-asserted-by": "publisher",
      "first-page": "89",
      "journal-title": "HRB Open Res",
      "key": "313_CR43",
      "unstructured": "Seoighe C, Bracken A, Buckley P, Doran P, Green R, Healy S et al (2020) The future of genomics in Ireland ? Focus on genomics for health [version 1; peer review: 2 approved]. HRB Open Res 3:89",
      "volume": "3",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s12687-015-0256-y",
      "author": "SA Lynch",
      "doi-asserted-by": "publisher",
      "first-page": "119",
      "issue": "2",
      "journal-title": "J Community Genet",
      "key": "313_CR44",
      "unstructured": "Lynch SA, Borg I (2016) Wide disparity of clinical genetics services and EU rare disease research funding across Europe. J Community Genet 7(2):119–126",
      "volume": "7",
      "year": "2016"
    },
    {
      "key": "313_CR45",
      "unstructured": "Clark T, Giffney C, Lambert D, Peyton C, Turner J, White N et al. (2018) Irish association of genetic counsellors (IAGC): Setting up a professional body and working towards regulation, in 21st meeting of the irish society of human genetics. Dublin"
    },
    {
      "key": "313_CR46",
      "unstructured": "Review of the Clinical Genetics Medical Workforce in Ireland (2019) Health Service Executive National Doctors Training \u0026 Planning. Available from: https://www.hse.ie/eng/staff/leadership-education-development/met/plan/specialty-specific-reviews/clinical-genetics-2019.pdf. Accessed 1 Jun 2022"
    },
    {
      "DOI": "10.1007/s12687-020-00491-3",
      "author": "L Bradley",
      "doi-asserted-by": "publisher",
      "first-page": "121",
      "issue": "1",
      "journal-title": "J Community Genet",
      "key": "313_CR47",
      "unstructured": "Bradley L, Lynch SA (2021) Dying to see you? Deaths on a clinical genetics waiting list in the Republic of Ireland; what are the consequences? J Community Genet 12(1):121–127",
      "volume": "12",
      "year": "2021"
    },
    {
      "key": "313_CR48",
      "unstructured": "O'Shea MT, Collins C. A survey of GP experience with the work of the National Cancer Control Programme and their views in relation to service priorities 2016, National Cancer Control Programme and Irish College of General Practitioners. Available from: https://www.hse.ie/eng/services/list/5/cancer/pubs/reports/a-survey-of-gp-experience-with-the-work-of-the-national-cancer-control-programme-and-their-views-in-relation-to-service-priorities.pdf. Accessed 1 Jun 2022"
    },
    {
      "author": "JM Pierle",
      "first-page": "60",
      "issue": "1",
      "journal-title": "Clin J Oncol Nurs",
      "key": "313_CR49",
      "unstructured": "Pierle JM, Mahon SM (2019) Genetic service delivery models: exploring approaches to care for families with hereditary cancer risk. Clin J Oncol Nurs 23(1):60–67",
      "volume": "23",
      "year": "2019"
    },
    {
      "key": "313_CR50",
      "unstructured": "ClinicalTrials.gov. Digital Delivery of Information About Genetic Testing for Breast Cancer (BRCA-DIRECT). 2022 07 July 2022]; Available from: https://clinicaltrials.gov/ct2/show/NCT04842799"
    },
    {
      "author": "J Barwell",
      "first-page": "273",
      "issue": "4",
      "journal-title": "Clin Med (Lond)",
      "key": "313_CR51",
      "unstructured": "Barwell J, Snape K, Wedderburn S (2019) The new genomic medicine service and implications for patients. Clin Med (Lond) 19(4):273–277",
      "volume": "19",
      "year": "2019"
    },
    {
      "DOI": "10.1001/jamanetworkopen.2019.4428",
      "author": "Z Kemp",
      "doi-asserted-by": "publisher",
      "issue": "5",
      "journal-title": "JAMA Netw Open",
      "key": "313_CR52",
      "unstructured": "Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E et al (2019) Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Netw Open 2(5):e194428",
      "volume": "2",
      "year": "2019"
    },
    {
      "DOI": "10.1038/srep29506",
      "author": "A George",
      "doi-asserted-by": "publisher",
      "first-page": "29506",
      "journal-title": "Sci Rep",
      "key": "313_CR53",
      "unstructured": "George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E et al (2016) Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep 6:29506",
      "volume": "6",
      "year": "2016"
    },
    {
      "DOI": "10.1038/s41598-020-60149-5",
      "author": "M Rumford",
      "doi-asserted-by": "publisher",
      "first-page": "3390",
      "issue": "1",
      "journal-title": "Sci Rep",
      "key": "313_CR54",
      "unstructured": "Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N et al (2020) Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: a study of 255 patients and its impact on their management. Sci Rep 10(1):3390",
      "volume": "10",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.ygyno.2017.01.030",
      "author": "M Kentwell",
      "doi-asserted-by": "publisher",
      "first-page": "130",
      "issue": "1",
      "journal-title": "Gynecol Oncol",
      "key": "313_CR55",
      "unstructured": "Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E et al (2017) Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol 145(1):130–136",
      "volume": "145",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41431-020-0692-y",
      "author": "N Flaum",
      "doi-asserted-by": "publisher",
      "first-page": "1541",
      "issue": "11",
      "journal-title": "Eur J Hum Genet",
      "key": "313_CR56",
      "unstructured": "Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J et al (2020) Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. Eur J Hum Genet 28(11):1541–1547",
      "volume": "28",
      "year": "2020"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-105140",
      "author": "B Rahman",
      "doi-asserted-by": "publisher",
      "first-page": "195",
      "issue": "3",
      "journal-title": "J Med Genet",
      "key": "313_CR57",
      "unstructured": "Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M et al (2019) Mainstreamed genetic testing for women with ovarian cancer: first-year experience. J Med Genet 56(3):195–198",
      "volume": "56",
      "year": "2019"
    },
    {
      "DOI": "10.12968/bjon.2020.29.10.S6",
      "author": "N Scott",
      "doi-asserted-by": "publisher",
      "first-page": "S6",
      "issue": "10",
      "journal-title": "Br J Nurs",
      "key": "313_CR58",
      "unstructured": "Scott N, O’Sullivan J, Asgeirsson K, Macmillan D, Wilson E (2020) Changing practice: moving to a specialist nurse-led service for BRCA gene testing. Br J Nurs 29(10):S6-s13",
      "volume": "29",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s10689-020-00160-x",
      "author": "EM Grindedal",
      "doi-asserted-by": "publisher",
      "first-page": "133",
      "issue": "2",
      "journal-title": "Fam Cancer",
      "key": "313_CR59",
      "unstructured": "Grindedal EM, Jørgensen K, Olsson P, Gravdehaug B, Lurås H, Schlichting E et al (2020) Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway. Fam Cancer 19(2):133–142",
      "volume": "19",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s10689-021-00277-7",
      "author": "K Bokkers",
      "doi-asserted-by": "publisher",
      "first-page": "295",
      "issue": "3",
      "journal-title": "Fam Cancer",
      "key": "313_CR60",
      "unstructured": "Bokkers K, Zweemer RP, Koudijs MJ, Stehouwer S, Velthuizen ME, Bleiker EMA et al (2022) Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer. Fam Cancer 21(3):295–304",
      "volume": "21",
      "year": "2022"
    },
    {
      "key": "313_CR61",
      "unstructured": "Hegarty J, Flaherty SJ, Egan S, Jones MM, Odisigo C, Chakraborty S, O'Reilly D, Saab MM. (2021) The unmet need in cancer genetic services: conducting an environmental scan of the cancer genetics services in an Irish context underpinned by a mixed methods approach. Irish Cancer Society www.cancer.ie"
    },
    {
      "DOI": "10.1038/gim.2015.30",
      "author": "S Richards",
      "doi-asserted-by": "publisher",
      "first-page": "405",
      "issue": "5",
      "journal-title": "Genet Med",
      "key": "313_CR62",
      "unstructured": "Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17(5):405–423",
      "volume": "17",
      "year": "2015"
    },
    {
      "DOI": "10.1016/j.cancergen.2017.02.001",
      "author": "TP McVeigh",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Cancer Genet",
      "key": "313_CR63",
      "unstructured": "McVeigh TP, Cody N, Carroll C, Duff M, Farrell M, Bradley L et al (2017) Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series. Cancer Genet 214–215:1–8",
      "volume": "214–215",
      "year": "2017"
    },
    {
      "key": "313_CR64",
      "unstructured": "NICE guideline 2013: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. (2013)"
    },
    {
      "DOI": "10.1038/bjc.2013.730",
      "author": "AJ Lee",
      "doi-asserted-by": "publisher",
      "first-page": "535",
      "journal-title": "Br J Cancer",
      "key": "313_CR65",
      "unstructured": "Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC (2013) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 110:535",
      "volume": "110",
      "year": "2013"
    },
    {
      "author": "E Mazzola",
      "first-page": "147",
      "issue": "Suppl 2",
      "journal-title": "Cancer Inform",
      "key": "313_CR66",
      "unstructured": "Mazzola E, Blackford A, Parmigiani G, Biswas S (2015) Recent enhancements to the genetic risk prediction model BRCAPRO. Cancer Inform 14(Suppl 2):147–157",
      "volume": "14",
      "year": "2015"
    },
    {
      "DOI": "10.1158/1055-9965.EPI-20-1319",
      "author": "T Carver",
      "doi-asserted-by": "publisher",
      "first-page": "469",
      "issue": "3",
      "journal-title": "Cancer Epidemiol Biomark Prev",
      "key": "313_CR67",
      "unstructured": "Carver T, Hartley S, Lee A, Cunningham AP, Archer S, de Babb VC et al (2021) CanRisk tool-a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemiol Biomark Prev 30(3):469–473",
      "volume": "30",
      "year": "2021"
    },
    {
      "DOI": "10.1136/jmg.2009.067850",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "811",
      "issue": "12",
      "journal-title": "J Med Genet",
      "key": "313_CR68",
      "unstructured": "Evans DG, Lalloo F, Cramer A, Jones EA, Knox F, Amir E et al (2009) Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 46(12):811–817",
      "volume": "46",
      "year": "2009"
    },
    {
      "DOI": "10.1016/j.ajog.2017.06.038",
      "author": "R Manchanda",
      "doi-asserted-by": "publisher",
      "first-page": "578.e1",
      "issue": "5",
      "journal-title": "Am J Obstet Gynecol",
      "key": "313_CR69",
      "unstructured": "Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans DG et al (2017) Cost-effectiveness of population based BRCA testing with varying ashkenazi jewish ancestry. Am J Obstet Gynecol 217(5):578.e1-578.e12",
      "volume": "217",
      "year": "2017"
    },
    {
      "DOI": "10.1136/jmg.2005.031989",
      "author": "DGR Evans",
      "doi-asserted-by": "publisher",
      "first-page": "e39",
      "issue": "7",
      "journal-title": "J Med Genet",
      "key": "313_CR70",
      "unstructured": "Evans DGR, Lalloo F, Wallace A, Rahman N (2005) Update on the manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 42(7):e39–e39",
      "volume": "42",
      "year": "2005"
    },
    {
      "DOI": "10.1001/jama.297.23.2587",
      "author": "JN Weitzel",
      "doi-asserted-by": "publisher",
      "first-page": "2587",
      "issue": "23",
      "journal-title": "JAMA",
      "key": "313_CR71",
      "unstructured": "Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR et al (2007) Limited family structure and brca gene mutation status in single cases of breast cancer. JAMA 297(23):2587–2595",
      "volume": "297",
      "year": "2007"
    },
    {
      "key": "313_CR72",
      "unstructured": "NIH. The Cost of Sequencing a Human Genome. 2016; Available from: https://www.genome.gov/27565109/the-cost-of-sequencing-a-human-genome/. Accessed 1 Jun 2022"
    },
    {
      "DOI": "10.1093/jnci/djx265",
      "author": "R Manchanda",
      "doi-asserted-by": "publisher",
      "first-page": "714",
      "issue": "7",
      "journal-title": "J Natl Cancer Inst",
      "key": "313_CR73",
      "unstructured": "Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A et al (2018) Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J Natl Cancer Inst 110(7):714–725",
      "volume": "110",
      "year": "2018"
    },
    {
      "key": "313_CR74",
      "unstructured": "Kennedy JM (2017) National Cancer Strategy 2017–2026, An Roinn Sláinte. Available from: https://www.gov.ie/en/publication/a89819-national-cancer-strategy-2017-2026/. Accessed 1 Jun 2022"
    },
    {
      "DOI": "10.12968/bjon.2016.25.12.690",
      "author": "N Percival",
      "doi-asserted-by": "publisher",
      "first-page": "690",
      "issue": "12",
      "journal-title": "Br J Nurs",
      "key": "313_CR75",
      "unstructured": "Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E et al (2016) The integration of BRCA testing into oncology clinics. Br J Nurs 25(12):690–694",
      "volume": "25",
      "year": "2016"
    },
    {
      "key": "313_CR76",
      "unstructured": "Davies S (2016) Chief medical officer’s summary, in annual report of the chief medical officer—generation genome C. Langenberg, Editor"
    },
    {
      "DOI": "10.1200/JCO.2016.67.0554",
      "author": "KN Maxwell",
      "doi-asserted-by": "publisher",
      "first-page": "4183",
      "issue": "34",
      "journal-title": "J Clin Oncol",
      "key": "313_CR77",
      "unstructured": "Maxwell KN, Domchek SM, Nathanson KL, Robson ME (2016) Population frequency of germline BRCA1/2 mutations. J Clin Oncol 34(34):4183–4185",
      "volume": "34",
      "year": "2016"
    },
    {
      "DOI": "10.1007/s11845-021-02637-9",
      "author": "JK McHugh",
      "doi-asserted-by": "publisher",
      "first-page": "1427",
      "issue": "3",
      "journal-title": "Ir J Med Sci",
      "key": "313_CR78",
      "unstructured": "McHugh JK, Offiah G, Daly S, El Beltagi N, Barry MK, O’Reilly S et al (2022) Postgraduate training in cancer genetics-a cross-specialty survey exploring experience of clinicians in Ireland. Ir J Med Sci 191(3):1427–1434",
      "volume": "191",
      "year": "2022"
    },
    {
      "DOI": "10.1038/ejhg.2016.138",
      "author": "M Coakley",
      "doi-asserted-by": "publisher",
      "first-page": "167",
      "issue": "2",
      "journal-title": "Eur J Hum Genet",
      "key": "313_CR79",
      "unstructured": "Coakley M, Cleary V, Power N, O’Reilly S (2017) BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision. Eur J Hum Genet 25(2):167–168",
      "volume": "25",
      "year": "2017"
    },
    {
      "DOI": "10.1016/S0140-6736(03)12856-5",
      "author": "F Lalloo",
      "doi-asserted-by": "publisher",
      "first-page": "1101",
      "issue": "9363",
      "journal-title": "Lancet",
      "key": "313_CR80",
      "unstructured": "Lalloo F, Varley J, Ellis D, Moran A, O’Dair L, Pharoah P et al (2003) Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361(9363):1101–1102",
      "volume": "361",
      "year": "2003"
    },
    {
      "DOI": "10.1200/JCO.2008.16.6959",
      "author": "KD Gonzalez",
      "doi-asserted-by": "publisher",
      "first-page": "1250",
      "issue": "8",
      "journal-title": "J Clin Oncol",
      "key": "313_CR81",
      "unstructured": "Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ et al (2009) Beyond li fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250–1256",
      "volume": "27",
      "year": "2009"
    },
    {
      "DOI": "10.1038/sj.ejhg.5200289",
      "author": "MR Nelen",
      "doi-asserted-by": "publisher",
      "first-page": "267",
      "issue": "3",
      "journal-title": "Eur J Hum Genet",
      "key": "313_CR82",
      "unstructured": "Nelen MR, Kremer H, Konings IB, Schoute F, van Essen AJ, Koch R et al (1999) Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 7(3):267–273",
      "volume": "7",
      "year": "1999"
    },
    {
      "key": "313_CR83",
      "unstructured": "McGarrity TJ, Amos CI, Baker MJ. (2016) Peutz-Jeghers syndrome, in genereviews. In: MP Adam et al. (Eds). 2001: Seattle (WA): University of Washington, Seattle"
    },
    {
      "DOI": "10.1158/1055-9965.EPI-16-0693",
      "author": "AK Win",
      "doi-asserted-by": "publisher",
      "first-page": "404",
      "issue": "3",
      "journal-title": "Cancer Epidemiol Biomark Prev",
      "key": "313_CR84",
      "unstructured": "Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG et al (2017) Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomark Prev 26(3):404–412",
      "volume": "26",
      "year": "2017"
    },
    {
      "key": "313_CR85",
      "unstructured": "Idos G, Valle L. Lynch Syndrome. 2004 Feb 5 [Updated 2021 Feb 4]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022"
    },
    {
      "DOI": "10.3892/or.2017.5703",
      "author": "P Skerl",
      "doi-asserted-by": "publisher",
      "first-page": "279",
      "issue": "1",
      "journal-title": "Oncol Rep",
      "key": "313_CR86",
      "unstructured": "Skerl P, Krajc M, Blatnik A, Novakovic S (2017) Genetic testing and counseling of a recipient after bone marrow transplant from a sibling harboring a germline BRCA1 pathogenic mutation. Oncol Rep 38(1):279–282",
      "volume": "38",
      "year": "2017"
    },
    {
      "key": "313_CR87",
      "unstructured": "HSE National Cancer Control Programme BRCA Testing (PARP Inhibitors). 2021 08 July 2022"
    },
    {
      "key": "313_CR88",
      "unstructured": "Kalachand R, Hennessy B, Byrne A, Casey O. (2019) Cancer trials ireland opens study to enable upfront and streamlined germline and somatic BRCA1/2 mutation testing in women with ovarian cancer"
    },
    {
      "key": "313_CR89",
      "unstructured": "HSE, HSE initiates a National Genetics and Genomics Strategy for Ireland (Press Release) 2022, available from https://www.hse.ie/eng/services/news/media/pressrel/hse-initiates-a-national-genetics-and-genomics-strategy-for-ireland.html. Accessed 1 Jun 2022."
    },
    {
      "key": "313_CR90",
      "unstructured": "NICE, Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer (Update of clinical guideline 14 and 41). 2017. Accessed 1 Jun 2022"
    }
  ],
  "reference-count": 90,
  "references-count": 90,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s10689-022-00313-0"
    }
  },
  "score": 0,
  "short-container-title": [
    "Familial Cancer"
  ],
  "source": "Crossref",
  "title": [
    "A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "22"
}